The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted the Conditional Marketing Authorization (CMA) to the inactivated covid-19 vaccine candidate ‘VLA2001’ developed by Valneva in the adults aged between 18 to 50 years.
The novel corona virus vaccine of Valneva has been indicated for the initial active immunization of the high risk population for the prevention of carriage and symptomatic corona virus infection and also for the routine inoculation including addressing the novel corona virus variants.
The VLA2001 is comprised of the inactivated whole virus particles of the corona virus along with the high S-protein density, two adjuvants, alum and CpG 1018 of Dynavax Technologies. This authorization has come after the UK MHRA has found that, the covid-19 vaccine has met the needed standards of quality and safety.
Currently, the company is holding the talks with the government of Scotland for the purpose of delivering around 25,000 doses of the vaccine to the frontline workers and National Health Service in the country of Scotland.
Thomas Lingelbach, chief executive officer of Valneva said, the VLA2001 covid-19 vaccine has been the only inactivated whole virus covid-19 vaccine that is approved in the United Kingdom and this authorization can possibly pave the way for the availability of an alternative vaccine solution for the population of the United Kingdom.
He also said, they believe that, this new approval can also lead to the additional marketing authorizations in the several other regions of the world.
